| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3281397 | Clinical Gastroenterology and Hepatology | 2016 | 54 Pages |
Abstract
In a retrospective analysis of a large cohort of biologic-naive patients with CD, we found infliximab to be superior to adalimumab and certolizumab pegol for patient-relevant outcomes, without increased risk of serious infections.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Siddharth Singh, Herbert C. Heien, Lindsey R. Sangaralingham, Stephanie R. Schilz, Michael D. Kappelman, Nilay D. Shah, Edward V. Jr.,